|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6913768||TAKEDA PHARMS USA||Sustained release delivery of amphetamine salts|| |
(4 months ago)
|US9173857||TAKEDA PHARMS USA||Controlled dose drug delivery system|| |
(2 years from now)
|US8846100||TAKEDA PHARMS USA||Controlled dose drug delivery system|| |
(5 years from now)
Mydayis is owned by Takeda Pharms Usa.
Mydayis contains Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate.
Mydayis has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Mydayis are:
Mydayis was authorised for market use on 20 June, 2017.
Mydayis is available in capsule, extended release;oral dosage forms.
Mydayis can be used as treatment of attention deficit hyperactivity disorder.
The generics of Mydayis are possible to be released after 24 August, 2029.
|Drug Exclusivity||Drug Exclusivity Expiration|
|Pediatric Exclusivity (PED)||Mar 13, 2023|
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic